Abstract 1532P
Background
Combination therapy using FGFR inhibitors and Immune checkpoint inhibitors (ICIs) are being explored as a novel strategy for cancer patients (pts). Previously, we reported the preliminary antitumor activity of irreversible FGFR inhibitor futibatinib plus pembrolizumab in pts with advanced (adv) or metastatic esophageal carcinoma (EC). Here, updated results and tolerability in combination with chemotherapy are presented.
Methods
Pts who are ICI naïve (Cohort A) or ICI refractory (Cohort B) for adv or metastatic EC who have received at least one prior therapy with a fluorouracil and platinum-based drug were administrated with futibatinib plus pembrolizumab. In addition, pts who have not received prior treatment with any systemic chemotherapy received futibatinib 20 mg once daily (QD) plus pembrolizumab 200 mg, fluorouracil 800mg/m2 on days 1-5 and cisplatin 80mg/m2 every 3weeks in Cohort D. Primary endpoint was overall response rate (ORR) in Cohort A and B, and dose-limiting toxicity (DLT) in Cohort D.
Results
As of March 15, 2023, 31 pts (Cohort A), 50 pts (Cohort B) and 11 pts (Cohort D) were enrolled. As results of the analysis for the cut-off data, confirmed partial responses (PRs) were observed in 11 pts in Cohort A; ORR was 39% with DCR of 75%. In Cohort B, confirmed PRs were observed in 3 pts; ORR was 6% with DCR of 57%. DLT was observed in one pt (Grade 3, Stomatitis) in Cohort D and the RD of futibatinib in combination with pembrolizumab and chemotherapy was determined as 20 mg QD. In Cohort D, most common TRAEs (N=11; all grade, grade ≥3) were hyperphosphatemia (82%, 0%) and stomatitis (82%, 9.1%). Of the 8 pts evaluated for efficacy in Cohort D, confirmed PRs and unconfirmed PRs were observed in 2 pts and 5 pts (5 pts are ongoing), respectively.
Conclusions
Futibatinib plus pembrolizumab showed encouraging antitumor activity in ICIs naïve adv or metastatic EC pts. Futibatinib plus pembrolizumab and chemotherapy showed no new safety signals and manageable safety profile, with promising antitumor activity in pts with adv or metastatic EC who have not received prior treatment with systemic chemotherapy.
Clinical trial identification
jRCT2080224975.
Editorial acknowledgement
Legal entity responsible for the study
Taiho Pharmaceutical Co., Ltd.
Funding
Taiho Pharmaceutical Co., Ltd., Merck & Co., Inc.
Disclosure
S. Yamamoto: Financial Interests, Personal and Institutional, Principal Investigator, Speaker's Bureau: MSD; Financial Interests, Personal, Speaker’s Bureau: Ono, Bristol Myers Squibb, Taiho; Financial Interests, Personal, Writing Engagement: M3; Financial Interests, Personal, Expert Testimony: Hokuto. K. Muro: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Ono, Chugai; Financial Interests, Personal, Invited Speaker: Eli Lilly, Ono, Daiichi Sankyo, Taiho, Bristol Myers Squibb, Takeda; Financial Interests, Institutional, Research Grant, Including local PI as role: Astellas, Amgen, Sanofi, Daiichi Sankyo, Taiho, MSD, Pfizer, Merck Biopharma, Eisai, Ono, Novartis; Financial Interests, Personal, Steering Committee Member: Chugai, AstraZeneca, Amgen; Non-Financial Interests, Principal Investigator: Takeda. K. Nishino: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical Co., Ltd., NSD, Amgen, Janssen Pharmaceutical K.K., Novartis Pharmaceuticals, Eli Lilly Japan, Takeda Pharmaceutical Co., Ltd., Chugai pharmaceutical, Nippon Boehringer Ingelheim, Nippon Kayaku; Financial Interests, Institutional, Other, Research grant: Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD, AbbVie, Daiichi Sankyo Company, Ltd., Amgen, Sanofi K.K., Janssen Pharmaceutical K.K., Novartis Pharmaceuticals, Pfizer, Eli Lilly, Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai pharmaceutical, Merus, AstraZeneca; Financial Interests, Institutional, Other, Research grant: Eisai Co., Ltd.; Financial Interests, Personal, Invited Speaker, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker, Advisory Board: Merck Biopharma Co., Ltd., AstraZeneca. H. Kawakami: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb Co. Ltd., Ono Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd., Bayer Yakuhin Ltd, Eli Lilly Japan K.K., MSD K.K., Chugai Pharmaceutical Co. Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., Taiho Pharmaceutical Co. Ltd.; Financial Interests, Personal, Advisory Board: Daiichi Sankyo Co. Ltd.; Financial Interests, Personal, Other, Lecture: GSKK.K, Otsuka Pharmaceutical Co., Ltd.; Financial Interests, Institutional, Research Grant, Investigator-Initiated Trial: Bristol Myers Squibb Co. Ltd.; Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical Co. Ltd, Eisai Co., Ltd., Kobayashi Pharmaceutical Co. Ltd., Parexel International Corp., PRA Health Sciences, EPS Corporation., Kissei Pharmaceutical Co., Ltd., EPS International Co., Ltd,., MSD K.K., Ono Pharmaceutical Co., Ltd., PPD-SNBL K.K, SymBio Pharmaceuticals Limited., IQVIA Services Japan K.K., Syneos Health Clinical K.K., Nippon Kayaku Co., Ltd., EP-CRSU Co., Ltd., Mebix, Inc., Bristol Myers Squibb K.K., Janssen Pharmaceutical K.K., Eisai Co., Ltd., AstraZeneca K.K., Mochida Pharmaceutical Co., Ltd., Covance Japan Inc., Japan Clinical Research Operations, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., GSK K.K., Sanofi K.K., Nippon Boehringer Ingelheim Co., Ltd., Sysmex Corporation, Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., SRL, Inc., Daiichi Sankyo Co., Ltd., Amgen Inc., Medical Research Support, Eli Lilly Japan K.K. T. Kojima: Financial Interests, Institutional, Principal Investigator: BeiGene Ltd., MSD K.K., Amgen Inc., Shionogi & Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical CO.,LTD., Taiho Pharmaceutical Co., Ltd., Parexel International; Financial Interests, Institutional, Research Grant: EPS Corporation.; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Ono Pharmaceutical Co., Ltd., Covidien Japan, Inc., MSD K.K., Taiho Pharmaceutical Co., Ltd.; Financial Interests, Personal, Writing Engagement: MSD K.K.; Financial Interests, Personal, Advisory Board: Merck Biopharma Co., Ltd. N. Machida: Financial Interests, Personal, Speaker’s Bureau: MSD, Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, Daiichi Sankyo, Inc., Taiho Pharmaceutical Co., Ltd., Yakult, Eli Lilly Japan K.K., Merck Biopharma Japan, Nichi-Iko. H. Hirai: Other, Personal, Full or part-time Employment: Taiho Pharmaceutical Co. Ltd.; Financial Interests, Personal, Stocks/Shares: Otsuka HD. M. Chisamore: Other, Personal, Full or part-time Employment: Merck & Co., Inc; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. K. Chin: Financial Interests, Personal, Speaker’s Bureau: Taiho Pharma, Ono Pharmaceutical Co, Ltd., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Merck & Co., Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1478P - Circulating pre-treatment T-Cell receptor repertoire as a predictive biomarker in non-small cell lung cancer patients treated with pembrolizumab
Presenter: Elin Gray
Session: Poster session 21
1479P - Association between high baseline low density neutrophils and resistance to immunotherapy in untreated non-small cell lung cancer: Molecular characterization of low-density neutrophils
Presenter: Hugo Arasanz
Session: Poster session 21
1480P - Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors
Presenter: Jonas Saal
Session: Poster session 21
1481P - Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Jose Miguel Jurado García
Session: Poster session 21
1482P - Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
Presenter: Jun Sakakibara-Konishi
Session: Poster session 21
1483P - Challenge of systemic first-line treatment of elderly lung cancer patients
Presenter: Konstantinos Ferentinos
Session: Poster session 21
1484P - Impact of concomitant KRAS/STK11 or KRAS/KEAP1 mutations on response to immune checkpoint inhibition in NSCLC: A real-world data analysis
Presenter: Louisa Hempel
Session: Poster session 21
1485P - Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice
Presenter: Magdalena Knetki-Wroblewska
Session: Poster session 21
1486P - Treatment patterns and real-world clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era
Presenter: Sarah Sharman Moser
Session: Poster session 21
1487P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results
Presenter: Qi-Ming Wang
Session: Poster session 21